NCT03914794View on ClinicalTrials.gov

A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 2, 2020

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions
Bladder CancerNMIBCNon-Muscle Invasive Bladder CancerUrothelial Carcinoma Recurrent
Interventions
DRUG

Pemigatinib

Participants will take Pemigatinib once daily on days 1 through 28 of each cycle prior to standard of care TURBT.

Trial Locations (6)

13210

Associated Medical Professionals Urology, Syracuse

17604

Keystone Urology, Lancaster

19004

Midlantic Urology, Bala-Cynwyd

20016

Sibley Memorial Hospital, Washington D.C.

21205

Johns Hopkins School of Medicine - Sidney Kimmel Comprehensive Cancer Center, Baltimore

29572

Carolina Urologic Research Center, Myrtle Beach

Sponsors

Collaborators (1)

Incyte Corporation
All Listed Sponsors
collaborator

Incyte Corporation

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER